
    successful completion of part a. company decision to end early.
  
['lung diseases', 'pulmonary disease', 'cystic fibrosis', 'cystic fibrosis lung', 'cystic fibrosis pulmonary exacerbation', 'cystic fibrosis with exacerbation', 'respiratory tract disease', 'pulmonary inflammation', 'multi-antibiotic resistance', 'antibiotic resistant infection', 'lung infection', 'lung infection pseudomonal', 'lung; infection, atypical mycobacterium', 'burkholderia infections', 'burkholderia cepacia infection', 'lung inflammation']
['inhaled snsp113', 'inhaled placebo']

        Inclusion Criteria:

        Part A

          -  Healthy male adults ≥18 and ≤50 years of age at screening.

          -  Baseline FEV1 80-120% of predicted at Screening.

          -  Oxygen saturation of ≥ 96% on room air as determined by pulse oximetry at Screening.

          -  Screening laboratory tests within normal limits.

        Part B

          -  Female and Male subjects who are ≥18 years of age and a confirmed diagnosis of CF.

          -  FEV1 >50% of predicted.

          -  Oxygen saturation of ≥ 94% on room air as determined by pulse oximetry at Screening.

          -  Stable CF pulmonary disease as judged by the Investigator.

        Exclusion Criteria:

        Part A

          -  Any history of any form of lung disease or any systemic disease that may affect the
             lung or pulmonary function.

          -  Former regular smoker or has smoked tobacco or cannabis products within the last 30
             days.

          -  Any history of any form of liver disease, renal disease, cardiac disease, hematologic
             disease, neurologic disease, atopy or any chronic condition.

          -  Participation in one or more healthy subject studies within the prior 3 months.

        Part B

          -  Participation in a clinical trial involving receipt of an investigational product
             within the 30 days prior to screening.

          -  Female subjects who are pregnant (a negative serum pregnancy test must be demonstrated
             at screening), have a positive pregnancy test, are lactating or who plan to become
             pregnant within 90 days after dosing.

          -  Subjects requiring supplemental oxygen.

          -  Hemoptysis of >5 mL within 12 weeks of screening.

          -  Listed for organ transplantation.
      